文献速递淋巴瘤造血干细胞移植与细胞治疗

成人T淋巴母细胞淋巴瘤异基因造血干细胞移植:中国多中心真实世界分析

Allogeneic haematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: A real-world multicentre analysis in China.
PubMed 文献 · Br J Haematol · 2024-04-25

这项多中心真实世界研究纳入中国五家移植中心的130例Ann Arbor III或IV期成人T淋巴母细胞淋巴瘤患者,评估异基因造血干细胞移植的结局与安全性。移植后2年疾病进展累积发生率为21.0%,无进展生存、总生存和非复发死亡概率分别为69.8%、79.5%和9.2%。诊断时中枢神经系统受累和未缓解状态移植与较差结局相关。

要点

  • 移植后2年疾病进展累积发生率21.0%,无进展生存69.8%,总生存79.5%,非复发死亡9.2%。
  • 中枢神经系统受累者疾病进展累积发生率57.1% vs 无受累者18.9%(HR 3.78,p=0.014)。
  • 未缓解移植者无进展生存49.2% vs 完全或部分缓解移植者72.7%(HR 2.21,p=0.041)。

核心结论

  • 真实世界数据显示,异基因造血干细胞移植似乎是Ann Arbor III或IV期成人T淋巴母细胞淋巴瘤的有效治疗。

研究设计与样本

  • 多中心真实世界研究,纳入中国五家移植中心共130例年龄>16岁的Ann Arbor III或IV期T淋巴母细胞淋巴瘤患者,均接受异基因造血干细胞移植。

主要发现

  • 移植后2年疾病进展累积发生率为21.0%,无进展生存概率69.8%,总生存概率79.5%,非复发死亡概率9.2%。
  • 中枢神经系统受累患者疾病进展累积发生率57.1% vs 无中枢神经系统受累患者18.9%(HR 3.78,p=0.014)。
  • 未缓解状态移植患者无进展生存49.2% vs 完全缓解或部分缓解状态移植患者72.7%(HR 2.21,p=0.041)。
  • 骨髓受累且移植前达完全缓解的患者中,移植前可测量残留病阳性者无进展生存62.7% vs 可测量残留病阴性者86.8%(HR 1.94,p=0.036)。
  • 多因素分析显示,诊断时中枢神经系统受累和未缓解状态移植与疾病进展相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this multicentre, real-world study, we aimed to identify the clinical outcomes and safety of allogeneic haematopoietic stem cell transplantation (allo-HSCT) in T-lymphoblastic lymphoma (T-LBL). A total of 130 Ann Arbor stage III or IV T-LBL patients (>16 years) treated with allo-HSCT across five transplant centres were enrolled. The 2-year cumulative incidence of disease progression, the probabilities of progression-free survival (PFS), overall survival (OS) and non-relapse mortality (NRM) after allo-HSCT were 21.0%, 69.8%, 79.5% and 9.2% respectively. Patients with central nervous system (CNS) involvement had a higher cumulative incidence of disease progression compared with those without CNS involvement (57.1% vs. 18.9%, HR 3.78, p = 0.014). Patients receiving allo-HSCT in non-remission (NR) had a poorer PFS compared with those receiving allo-HSCT in complete remission (CR) or partial remission (49.2% vs. 72.7%, HR 2.21, p = 0.041). Particularly for patients with bone marrow involvement and achieving CR before allo-HSCT, measurable residual disease (MRD) positivity before allo-HSCT was associated with a poorer PFS compared with MRD negativity (62.7% vs. 86.8%, HR 1.94, p = 0.036). On multivariate analysis, CNS involvement at diagnosis and receiving allo-HSCT in NR were associated with disease progression. Thus, our real-world data suggested that allo-HSCT appeared to be an effective therapy for adult T-LBL patients with Ann Arbor stage III or IV disease.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Huo W, Gao L, Song K, et al. Allogeneic haematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: A real-world multicentre analysis in China. Br J Haematol. 2024. PMID: 38664918. doi:10.1111/bjh.19481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。